Recently, recombinant human erythropoietin produced by gene technology has become available in the treatment of renal anemia in dialysis patients. A papulous skin reaction as well as a generally increased pruritus has been reported in several patients following 2 to 3 months of treatment. Following a course of recurrence lasting several weeks, the skin changes cleared up spontaneously. In one female patient, treatment was discontinued due to skin reaction.